Allergan Restasis Growth May Come Through DTC Ads, Marketing Partner
Executive Summary
Allergan may pursue a direct-to-consumer advertising campaign to grow sales of the dry eye therapy Restasis (cyclosporine ophthalmic emulsion .05%)
You may also be interested in...
Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December
Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent
Allergan spin-off ASTI will begin Phase III trials of memantine in glaucoma by July.
ALLERGAN SPECIALTY THERAPEUTICS MEMANTINE PHASE III TRIALS will commence in July 1998, the company stated in a recent SEC registration document. Two trials are planned; one will be in open-angle glaucoma patients receiving concomitant intraocular pressure-lowering drugs and the other will be in ocular hypertensive patients not receiving intraocular pressure- lowering drugs.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011